I suppose these patients will be monitored far more carefully after what happened with Tysabri.
I wonder about that, Harry. Maybe they will be, but will they be monitored for the correct risks?
I think I'll go ahead and start a new thread on the research I did with regard to daclizumab. Might as well. Since when do I mind getting Biogen in a uproar?